Smarter leaders trust GlobalData

Data Insights Innovation in pharma: PDK-1 inhibitors

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Johnson & Johnson

F. Hoffmann-La Roche Ltd

Vertex Pharmaceuticals Inc

Exelixis Inc

Alnylam Pharmaceuticals Inc

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates, and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

PDK-1 inhibitors is a key innovation area in the pharmaceutical industry

Phosphoinositide-dependent kinase-1 (PDK-1) inhibitors are a class of compounds designed to target and inhibit the activity of PDK-1, a protein kinase that plays a crucial role in regulating cell signaling pathways. PDK-1 is part of the phosphoinositide 3-kinase (PI3K) pathway, which is involved in cell growth, proliferation, and survival. Inhibiting PDK-1 activity can have therapeutic potential, particularly in the context of cancer and other diseases where dysregulated cell signaling contributes to the disease pathogenesis.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 185+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of PDK-1 inhibitors.

Key players in PDK-1 inhibitors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to PDK-1 inhibitors

F. Hoffmann-La Roche is one of the leading patent filers in PDK-1 inhibitors. F. Hoffmann-La Roche, commonly known as Roche, is a pharmaceutical company that has been involved in the development of kinase inhibitors, a class of drugs that target specific protein kinases involved in various cellular signaling pathways. Vemurafenib is a kinase inhibitor developed by Roche in collaboration with Plexxikon. It is used to treat patients with melanoma, whose tumors have a specific mutation in the BRAF gene known as the V600E mutation. Cobimetinib is another kinase inhibitor developed by Roche and Exelixis. Vertex Pharmaceuticals and Johnson & Johnson are some of the other key patent filers in PDK-1 inhibitors.

In terms of application diversity, Raze Therapeutics leads the pack, while BioMarin Pharmaceutical and Swiss Rockets stood in second and third positions, respectively.

By means of geographic reach, F. Hoffmann-La Roche held the top position, followed by C. H. Boehringer Sohn and Pierre Fabre Foundation.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.